| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2669 |
| Trial ID | NCT04855136 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Co-treatment | CC-220 |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Celgene |
| Other ID(s) | BB2121-MM-007|2020-003248-10 |
| Cohort1: bb2121_CC-220 | |||||||||
|
|||||||||
| Cohort2: bb2121_BMS-986405 | |||||||||
|
|||||||||